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Chapter 4
Regulation of vascular smooth muscle cell
differentiation
Eva M. Rzucidlo, MD, Kathleen A. Martin, PhD, and Richard J. Powell, MD, Lebanon, NH
Vascular smooth muscle cell (VSMC) differentiation is an essential component of vascular development. These cells
perform biosynthetic, proliferative, and contractile roles in the vessel wall. VSMCs are not terminally differentiated and
are able to modulate their phenotype in response to changing local environmental cues. There is clear evidence that
alterations in the differentiated state of the VSMC play a critical role in the pathogenesis of atherosclerosis and intimal
hyperplasia, as well as in a variety of other major human diseases, including hypertension, asthma, and vascular
aneurysms. The focus of this review is to provide an overview of the current state of knowledge of molecular mechanisms
involved in controlling phenotypic switching of SMCs, with particular focus on examination of signaling pathway that
regulate this process. ( J Vasc Surg 2007;45:25A-32A.)Vascular smooth muscle cells (VSMC) are highly spe-
cialized cells whose principal function is contraction and
regulation of blood vessel tone, blood pressure, and blood
flow. VSMCswithin adult blood vessels exhibit a low rate of
proliferation, low synthetic activity, and express a unique
repertoire of contractile proteins, ion channels, and signal-
ing molecules required for the cell’s contractile function
that is clearly unique compared with any other cell type.1
Unlike either skeletal or cardiac myocytes that are terminally
differentiated, VSMCs retain remarkable plasticity and can
undergo rather profound and reversible changes in phenotype
in response to changes in local environmental cues.1
In a mature blood vessel, VSMCs exhibit a “contractile”
or differentiated phenotype characterized by the expression of
contractilemarkers specific to smoothmuscle, such as smooth
muscle myosin heavy chain, smooth muscle -actin, h-caldes-
mon, and calponin, which are important for the regulation of
contraction.1 Upon injury such as after angioplasty, stenting,
or bypass surgery, VSMCs dedifferentiate and re-enter the cell
cycle. They demonstrate an increased rate of proliferation,
migration, and synthesis of extracellular matrix components,
and at the same time, demonstrate a decrease in expression of
SM-specific contractile markers.2,3 This dedifferentiated phe-
notype plays a major pathophysiologic role in the develop-
ment of atherosclerosis, restenosis after angioplasty or bypass,
and hypertension
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doi:10.1016/j.jvs.2007.03.001VSMC plasticity is also important during normal vas-
cular development, however. During this process, VSMCs,
which initially in a dedifferentiated, state exhibit a high rate
of proliferation, migration, and production of extracellular
matrix components such as collagen, elastin, and proteo-
glycans that make up a major portion of the blood vessel
wall, while at the same time acquiring contractile capabili-
ties. Once fully developed, however, VSMCs differentiate
into a contractile phenotype to assume the functions re-
quired of the mature arterial wall.
In the past, it was suggested that proliferation and
differentiation were coupled processes such that the loss of
VSMC differentiation markers was a prerequisite for the
ability of VSMCs to proliferate. It is now well established
that differentiation and proliferation are not necessarily
mutually exclusive processes and that many factors other
than the VSMC’s proliferation status influence differentia-
tion. In evidence of this, heparin, which is a powerful
inhibitor of VSMCgrowth in vitro and in vivo, has no effect
on VSMC differentiation in humans.4-6 Also, during late
embryogenesis and postnatal development, VSMCs are
known to have an extremely high rate of proliferation7; yet,
they undergo a rapid rate of induction of multiple VSMC
differentiation marker genes.8 Conversely, VSMCs within
advanced atherosclerotic lesions show a very low rate of
proliferation that approaches that of fully differentiated
VSMC but are also highly phenotypically modulated, as
evidenced by marked reductions in expression of VSMC
marker genes.9,10 These findings show that cessation of
proliferation alone is not sufficient to promote VSMC
differentiation.
Alterations in vascular smooth muscle cell pheno-
type during restenosis. During the process of restenosis,
VSMCs dedifferentiate from a contractile to synthetic phe-
notype after vascular wall injury. Processes such as endothe-
lial denudation, direct VSMC trauma, and the subsequent
release of multiple growth factors all play a role in promot-
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ferentiation, VSMCs migrate to the subintimal space, pro-
liferate, and secrete abundant amounts of extracellular
matrix. Extracellular matrix forms the bulk of the intimal
hyperplastic lesion that contributes to restenosis, the most
common cause of failure after vascular intervention or
reconstruction. Restenosis affects up to 30% to 40% of
coronary angioplasties. Recent advances in drug-eluting
stents may decrease the incidence but are unlikely to com-
pletely prevent this common problem.13
Alterations in vascular smooth muscle cell pheno-
type during atherosclerosis. During the development of
atherosclerosis, several processes similar to those that occur
during restenosis promote a dedifferentiated VSMC phe-
notype. VSMC dedifferentiation occurs after exposure to
multiple growth factors and inflammatory mediators re-
leased by activated macrophages and as a result of exposure
to oxidized low-density lipoproteins. During the formation
of atherosclerotic plaque, VSMCs in the dedifferentiated
phenotype migrate to the subintimal space and contribute
to the formation of a fibrous cap over the atherosclerotic
plaque. Interferon- released by activated macrophages
induces collagen synthesis by VSMCs, which is important
for the stabilization of the fibrous cap. VSMCs and macro-
phages release enzymes such as matrix metalloproteinases
that can destabilize the plaque, resulting in fibrous cap
disruption and arterial thrombosis.14
Alterations in vascular smooth muscle cell pheno-
type during arteriogenesis. During arteriogenesis,
VSMCs dedifferentiate to migrate along the outside of
newly formed endothelial tubes.15-17 Once the cells have
attained the proper orientation, they must differentiate
back into a contractile phenotype if a stable blood vessel is
to be formed.18 Similarly, during collateral blood vessel
formation, VSMCs must dedifferentiate to allow for vascu-
lar wall remodeling to form a larger blood vessel.17,18
Although there are certainly differences in the synthetic
phenotype of VSMCs in these diverse vascular processes,
the need for VSMCs to dedifferentiate from a contractile
phenotype is a common theme. Understanding the factors
that promote a differentiated phenotype is central to influ-
encing these processes.
Endothelial cell regulation of smooth muscle cell
phenotype. Hirschi et al16 have shown that endothelial
cells can promote VSMC differentiation in a VSMC pro-
genitor cell line. Using an under-agarose gel assay, these
investigators have shown that endothelial cells cultured
separately from the VSMC progenitor cell line 10T1/2
promote migration of this cell line toward endothelial cells.
Once the endothelial cells and 10T1/2 cells achieve close
contact, however, the endothelial cells promote differenti-
ation of the 10T1/2 cells to a VSMC phenotype.16 Our
laboratory and others have similarly shown that endothelial
cells maintain VSMCs in a differentiated phenotype. We
have shown that endothelial cells promote VSMC differen-
tiation from the synthetic phenotype into the contractile
phenotype as measured by cell morphology, differentiation
protein marker expression, and cell contractility.19-22Multiple animal studies support the concept that endo-
thelial cells maintain VSMCs in a differentiated phenotype.
In-vivo studies by Fingerle et al23 have demonstrated that
after arterial injury, rapid re-endothelialization of the arte-
rial surface results in decreased intimal hyperplasia com-
pared with areas that do not re-endothelialize.23 These
authors have not identified a substance derived from endo-
thelial cells that accounts for this phenomenon. Similarly,
implants containing endothelial cells applied to the adven-
titia of a balloon-injured artery results in favorable wall
remodeling.24 Several studies both in humans and animals
have shown that seeding endothelial cells on prosthetic
bypass grafts results in increased patency.25
Mechanisms of smooth muscle cell phenotype reg-
ulation. The intracellular signaling mechanisms that regu-
late VSMC phenotype are not well understood (Fig 1).
Several different signaling cascades have been implicated in
VSMC differentiation. Boerth et al26 have shown that
transfection with protein kinase G-I or  (PKG-I or
PKG-I), or the constitutively active catalytic domain of
PKG, results in VSMC differentiation as determined by
increased expression of the differentiation protein marker
smooth muscle smooth muscle myosin heavy chain-2.26 In
addition, Brophy et al,27 in collaboration with this group of
investigators, has gone on to show that inhibition of PKG
expression results in a dedifferentiated VSMC phenotype
that is unable to contract and that this can be reversed by
transfection with PKG.27
Reusch et al28 have shown that serum can promote a
differentiated phenotype and that this occurs through G
protein coupled receptor activation of the mitogen-
activated protein kinase/extracellular signal-regulated ki-
nase pathway (MEK). This effect can be blocked with the
MEK inhibitor U0126.28 These findings present a paradox
because serum is known to stimulate SMC migration,
proliferation and matrix synthesis.
Sobue et al29 have shown that VSMCs cultured on
laminin maintain a differentiated phenotype when treated
with insulin-like growth factor (IGF). These investigators
have shown that this process is mediated through the IGF
receptor and subsequent activation of the phosphoinositide
3-kinase (PI3K)/AKT pathway.29 This remains an interest
in our laboratory and will be discussed in more detail.
Subsequent work from this group has shown that cal-
cineurin, a downstream target of AKT, is involved in pro-
moting a differentiated VSMC phenotype.30 It is likely that
additional as yet unidentified laminin-regulated pathways
are also involved.
Transcriptional regulation of smooth muscle cell
phenotype. The transcriptional regulation of genes in-
volved in control of VSMC phenotype is poorly under-
stood. Several transcription factors and coregulators have
recently been shown to contribute to regulation of VSMC
phenotype. The GATA-6 transcription factor, a member of
the GATA family of zinc finger motif DNA-binding do-
main proteins, exhibits characteristics of a SMC-specific
master regulatory transcription factor. GATA-6 is ex-
pressed in quiescent SMC but is rapidly down-regulated in
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ferentiated SMCphenotype and promotes withdrawal from
the cell cycle by induction of p21cip.32,33
Mano et al31 have shown that after rat carotid balloon
catheter injury, VSMCs dedifferentiate into the synthetic
phenotype and that this is associated with a down-
regulation of GATA-6 DNA binding. Over-expression of
GATA-6 prevented SMC dedifferentiation, increased ex-
pression of SMC differentiation protein markers, and favor-
ably influenced arterial wall remodeling.31
Wada et al34 have shown that the smooth muscle
myosin heavy chain promoter is regulated by a functional
GATA-6 DNA regulatory element.34 Similarly, the pro-
moter of the 1-integrin gene, which is expressed exclu-
sively in the differentiated SMC phenotype, is also regu-
lated by a GATA element.35 Nishida et al36 have shown
that a triad of transcription factors act synergistically to
regulate the transcription of VSMC differentiated pheno-
type specific genes. These investigators have shown that
interactions between the serum response factor (SRF)/
CArG (CC(A/T-rich)6GG) box, TAAT sequence/ho-
meobox-binding protein, and GATA-6/GATA binding
site act together to promote transcription of smooth mus-
cle proteins specific to the differentiated phenotype.36
Several coactivators have been shown to affect GATA-6
DNA binding and transactivation. These include p300 and
friend of GATA (FOG), both of which may be involved in
regulating GATA-6 activity and thus may modulate tran-
Fig 1. Vascular smooth muscle cell (VSMC) phenotyp
with anticalponin antibody treated with ethanol (left) o
Right,Human VSMC grown in monolayers dedifferenti
causes differentiation of VSMC.) The differentiation stat
multiple external factors. This figure summarizes the m
Extracellular matrix; MMP, matrix metalloproteinase; S
inhibitor of matrix metalloproteinase.scription of proteins responsible for SMC differentiation.37Myocardin is a cardiac and smooth muscle-specific
coactivator of the ubiquitous SRF transcription factor.38
SRF binds to cis DNA regulatory elements called CArG
boxes (CC(A/T-rich)6GG), which are found in the pro-
moters of muscle-specific genes, as well as serum-inducible
genes such as c-fos that regulate proliferation.Upon discov-
ery of myocardin as a cell type specific cofactor, it became
apparent how SRF and these CArG motifs could mediate
two opposing patterns of gene expression. In promoters
such as c-fos, ternary complex factors such as Elk-1 are
phosphorylated by ERK1/2 in response to serum growth
factor stimulation. These bind to SRF, which is constitu-
tively bound toDNA, and lead to promoter transactivation.
In muscle-specific promoters, myocardin competes with
Elk-1 for binding to SRF.38 Myocardin-binding to SRF
promotes expression of smooth muscle specific genes. By
these mechanisms, myocardin and Elk-1 can act as binary
transcriptional switches that may regulate the differentiated
versus proliferative phenotypes in VSMC.31
MAMMALIAN TARGET OF RAPAMYCIN/P70
S6 KINASE 1 PATHWAY REGULATES
VASCULAR SMOOTH MUSCLE CELL
DIFFERENTIATION
The mammalian target of rapamycin (mTOR; also
known as FRAP or RAFT) signaling pathway regulates
translation initiation in response to amino acids, and effec-
tors of this pathway integrate nutrient-sufficiency signals
rkers. Immunohistochemical staining of human VSMC
nM rapamycin (right) for 48 hours in 2.5% calf serum.
a synthetic phenotype. Left, The addition of rapamycin
SMCs is highly plastic and dependent on integration of
markers during VSMC phenotypic modulation. ECM,
HC,smooth muscle-myosin heavy chain; TIMP, tissueic ma
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tion.39Much of what is known about this pathway has been
derived from studies using the macrolide antibiotic rapa-
mycin, which binds to mTOR as a complex with FKBP12
to inhibit mTOR function. Although mTOR is a ubiqui-
tously expressed protein kinase, some cell types are more
sensitive to its effects on proliferation than others. Rapamy-
cin is currently in use in clinical trials as an immunosuppres-
sant to prevent transplant rejection40 because lymphocyte
proliferation is highly rapamycin-sensitive.
Since receiving United States Food and Drug Admin-
istration approval in 2003, the use of the mTOR inhibitor
rapamycin on drug-eluting stents has decreased the inci-
dence of restenosis and the need for repeat revasculariza-
tions in coronary lesions.41,42 Although it is known that
rapamycin inhibits VSMC migration43 and proliferation44
in vitro and intimal hyperplasia in vivo, we have recently
demonstrated that rapamycin also induces differentiation in
cultures of synthetic phenotype VSMCs.45 VSMCs in cul-
ture rapidly undergo phenotypic dedifferentiation to the
synthetic phenotype after serial passages. Rapamycin treat-
ment of human VSMC induced a contractile morphology
and reduced protein and collagen synthesis by 40% to 60%.
There was a coordinated induction of cyclin-dependent
kinase inhibitor (p21cip, p27kip) and contractile protein
expression, which began as early as 2 hours after rapamycin
treatment, and was a sustained response as shown by in-
creased contractile protein expression up to 48 hours after
treatment (Fig 2).
Rapamycin is a known mTOR pathway inhibitor. We
have investigated which downstream effector of this path-
way was important in the regulation of VSMC differentia-
tion. One of the best-characterized effectors of the mTOR
pathway is S6 kinase 1 (S6K1). We used an adenovirus
strategy to determine if S6K1 was a critical regulator of
VSMCdifferentiation. Over-expression of S6K1 (both wild
type and rapamycin-resistant constructs) opposed
rapamycin-induced VSMC differentiation, thus showing
that S6K1 is a critical regulator of VSMC differentiation.
The most intriguing aspect of this work was the finding
that inhibition of mTOR by rapamycin induced new mes-
senger RNAs (mRNAs) encoding contractile proteins. Be-
cause calponin mRNA was undetectable in the vehicle-
treated dedifferentiated VSMCs and was rapidly induced, it
is likely due to new transcription. Similar induction of
smooth muscle myosin heavy chain mRNA suggests that
mTOR-dependent transcriptional regulation may be a
common mechanism among VSMC differentiation marker
proteins. Notably, the kinetics of contractile protein ex-
pression closely follows the induction of these messages.
Although the TOR pathway is known to regulate
nutrient-sensitive transcription factors in yeast,46 very little
is known about transcriptional control by mTOR in mam-
malian cells. Several studies, however, have reported that
rapamycin induces hematopoietic differentiation29,47,48
but inhibits adipocyte differentiation49 and chondrogene-
sis.50 Differential effects of rapamycin on differentiation in
other cell lines suggests that mTOR may indeed be animportant regulator of cell type-specific transcriptional pro-
cesses. We are currently evaluating mTOR-regulated
VSMC-specific transcription factor candidates.
Our data demonstrated that S6K1 opposed VSMC
differentiation. Others have shown that after vascular in-
jury, S6K1 becomes activated51; however, S6K1 inhibition
alone may not be sufficient for VSMC differentiation. We
found that AKT inhibition with LY-294002, which in turn
leads to S6K1 inhibition,52 did not promote VSMC differ-
entiation (Fig 2). We postulate that whereas S6K1 may
oppose differentiation, promotion of differentiation also
requires AKT-dependent prodifferentiation signals. Sup-
port of this hypothesis comes from studies by Sobue et al,39
who have demonstrated that IGF-I-induced VSMC differ-
entiation requires PI3K29 and that AKT is an important
mediator of visceral SMC differentiation.30 It is likely that
the full complement of signaling effectors activated down-
stream of IGF-I and PI3K results in a prodifferentiation
signal, despite activation of S6K1.
Rapamycin promotes vascular smooth muscle cell
differentiation through activation of the AKT pathway.
Signaling by mTOR is crucial in regulating cell growth
and proliferation in response to cellular environment,
Fig 2. Rapamycin induces vascular smooth muscle cell (VSMC)
contractile protein expression. A, Immunofluorescent anticalpo-
nin staining of bovine VSMC treated with ethanol (left) or 20 nM
rapamycin (right) for 48 hours in 2.5% calf serum. B, Top panel,
Antismooth muscle heavy chain (SM-MHC) SM2 western blot of
rat VSMC cultured with ethanol or 20 nM rapamycin in 2.5%
serum.Bottom panel,Anticalponin western blot of bovine VSMC
cultured with ethanol or 20 nM rapamycin in 2.5% serum. C,
Anticalponin Western blot of bovine VSMC in the presence of
vehicle or indicated drugs for 48 hours. Rap, 20 nmol/L rapamy-
cin; LY, 10 mol/L LY294002; SB, 10 mol/L SB203580; UO,
5 mol/L UO126. (Data from Martin KA, Rzucidlo EM, Me-
renick BL, et al, The mTOR/p70 S6K1 pathway regulates vascular
smooth muscle cell differentiation. Am J Physiol Cell Physiol
2004;286:C507-17.)including nutrient, energy, and oxygen sufficiency.52,53
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obesity, and cancer is becoming increasingly appreciated.
Notably, in insulin-responsive tissues such as skeletal
muscle and adipocytes, mTOR and S6K1 provide nega-
tive feedback to the insulin/IGF-I signaling pathway
through inhibitory serine phosphorylation of the insulin
receptor substrate-1 (IRS-1), which targets IRS-1 for
degradation.54,55 Inhibition of mTOR/S6K1 with rapa-
mycin relieves this repression of IRS-1 and facilitates its
activation of PI3K and AKT in response to insulin or IGF-I.
To date, this feedback-signaling network, which contrib-
utes to insulin resistance in type II diabetes,56,57 has not
been documented in VSMC. Phosphorylation of IRS-1 at
its tyrosine site recruits effector signaling proteins, allowing
for continued signaling through the pathway.58 These
changes in phosphorylation of IRS-1 can be seen as mobil-
ity shifts on sodium dodecyl sulfate polyacrylamide gel
electrophoresis.54,55
We recently have shown that inhibition of IRS-1 and its
subsequent signaling to AKT is probably the mechanism by
which S6K1 opposes VSMC differentiation (unpublished
data) We first demonstrated that rapamycin induced AKT
activation, as measured by phosphorylation of the critical
serine 473, in a time-dependentmanner.Wewere then able
to demonstrate a mobility shift of IRS-1 with the addition
of rapamycin. With the inhibition of S6K1 by rapamycin,
we found decreased serine phsophorylation of IRS-1 lead-
ing to decreased proteosomal degradation and stabilization
of IRS-1. With increase AKT activation, there is an increase
in VSMCdifferentiationmarkers such as contractile protein
expression. As we have shown before, over-expression of
rapamycin-resistant S6K1 decreased AKT activation and
opposed VSMC expression of differentiation markers such
as contractile proteins. To our knowledge, this is the first
demonstration of the existence of this feedback loop in
which the mTOR pathway, via IRS-1, attenuates PI3K
signaling in VSMC. Our findings confirm the importance
of the AKT pathway in VSMC phenotypic modulation.
EFFECT OF ENDOTHELIAL CELL AND
VASCULAR SMOOTH MUSCLE CELL
INTERACTION
Interactions between endothelial cells and VSMCs are
fundamental in diverse cardiovascular processes such as
arteriogenesis, collateral blood vessel development, athero-
sclerosis, and restenosis. Alterations in VSMC phenotype
occur in each of these processes. Endothelial denudation
has been suggested to contribute to the SMC proliferative
response to vessel injury by angioplasty or other catheter-
ization procedures. We have used a coculture approach to
dissect the molecular signals that are dependent on the
spatial relationship between endothelial cells and VSMCs.
Our laboratory and others have similarly shown that endo-
thelial cells maintain VSMCs in a differentiated phenotype.
We have shown that ECs promote SMC differentiation
from the synthetic to the contractile phenotype as mea-
sured by cell morphology, differentiation protein marker
expression, and cell contractility.19-22We have recently reported that endothelial cell cocul-
ture promotes a differentiated phenotype through activa-
tion of the AKT pathway in VSMCs.59 Coculture induces a
rapid, sustained activation of AKT in the VSMC, and
inhibition of AKT signaling with pharmacologic inhibitors
or dominant-negative AKT prevented endothelial cells
from inducing VSMC phenotypic modulation. Further-
more, we demonstrated that constitutively active AKT is
sufficient to promote redifferentiation of synthetic pheno-
type VSMCs cultured alone.
The mechanism by which endothelial cells regulate
SMC PI3K/AKT is presently unknown. We believe that a
soluble mediator derived from endothelial cells may pro-
mote VSMC phenotypic modulation. We have shown that
conditioned media from cocultured endothelial cells and
SMCs can promote SMC differentiation, but that the ki-
netics of the differentiation response is delayed relative to
coculture.60 Conditioned media from either endothelial
cells or VSMCs cultured alone does not induce differenti-
ation, however; in fact, conditioned media from endothe-
lial cells cultured alone induces VSMC proliferation, migra-
tion, and protein synthesis.61 We therefore hypothesize
that the coculture of endothelial cells and VSMCs pro-
motes release of a soluble mediator from the endothelial
cells that acts on VSMCs. We are presenting attempting to
identify this soluble mediator(s).
FUTURE DIRECTION
Prostacyclin as a mediator of vascular smooth mus-
cle cell differentiation. Our laboratory is also studying
how prostacyclin (PGI2), an endothelial cell–derived pros-
taglandin product of cyclooxygenase-2, promotes vascular
SMC differentiation through transcriptional mechanisms.
In blood vessels, it is produced predominantly by the
endothelial cells and released to act upon neighboring
VSMCs as well as circulating platelets.62 PGI2 has a very
short half-life and acts in a paracrine manner.
We recently reported that iloprost, a PGI2 mimetic,
induced dedifferentiated adult human VSMCs to a contrac-
tile differentiated phenotype based on an increased expres-
sion differentiation markers specific to smooth muscle,63 as
well as a change in morphology.63 In this study, we also
determined that the induction of the markers specific to
smooth muscle required iloprost Gs activation of the cyclic
adenosine monophosphate/protein kinase A(cAMP/PKA)
pathway. In addition, using a variety of approaches to
inhibit protein kinase A activity, we have shown that pro-
tein kinase A activation is necessary for iloprost-induced
VSMC differentiation.63
Pleiotropic effects of statins and vascular smooth
muscle cell differentiation. The beneficial effects of
statins are assumed to result from their ability to reduce
cholesterol biosynthesis. However, because mevalonic acid
is the precursor not only of cholesterol but also of many
nonsteriodal isoprenoid compounds, inhibition of 3-
hydroxy-3-methyl-glutaryl coenzyme A reductase results in
pleiotropic effects. Statins have previously been shown to
decrease proliferation and migration and increase apoptosis
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injury induces a phenotypic modulation toward a prolifer-
ative, dedifferentiated, migratory phenotype with increased
extracellular matrix secretion. This phenotypic switch con-
tributes to intimal hyperplasia. The effect of statins on
VSMC differentiation has not yet been reported.
We have recently demonstrated a novel effect of statins
on VSMC differentiation. Statins were able to inhibit
VSMC proliferation and extracellular matrix production
and also induced a contractile morphology and contractile
protein expression. We are presently investigating the
downstream targets of statins to better understand the
mechanism regulating their affect on VSMC differentia-
tion. This effect shows another potential mechanism for the
cardiovascular protective effects of statins.
CONCLUSION
The model that has evolved is that regulation of VSMC
differentiation is extremely complex and involves constant
interplay between environmental cues and the genetic pro-
gram that controls the coordinate expression of genes
characteristic of the VSMC lineage. The interplay of signal-
ing pathways within the cell are complex and overlapping.
Our work has focused on the importance of the PI3K
pathway in VSMC phenotypic modulation. This pathway
has become important not only in vascular biology but also
in diabetes and obesity. Better understanding of this path-
way and, more importantly, the transcriptional factor that
may be turned on or off by this pathway, may help to
determine a target for therapy in patients with vascular
disease (Fig 3).
Despite compelling evidence that phenotypic modula-
tion of the VSMC plays a key role in vascular injury repair
and in the development or progression, or both, of athero-
Fig 3. Our currentmodel of signaling pathways that regulate vascu-
lar smooth muscle cell (VSMC) differentiation. Rapamycin and a
soluble endothelial cell mediator regulate VSMC differentiation
through a feedback regulation of the insulin growth factor-I (IGF-
I)/insulin receptor substrate-1/phosphoinositide 3-kinase (PI3K)/
AKT pathway. Prostacyclin activation of the effector pathway Gs/
adenylyl cyclase/cyclic adenosine monophosphate (cAMP) /protein
kinase A (PKA) induces VSMCdifferentiation. Statins induce VSMC
differentiation through a yet undetermined pathway. mTOR, Mam-
malian target of rapamycin; S6K1, S6 kinase 1.sclerosis, relatively little is known about how this process isregulated in vivo. In fact, we are just beginning to under-
stand some of the molecular mechanisms and factors that
control transitions in the phenotypic state of the VSMC
associated with vascular injury, and we know almost noth-
ing about what controls these transitions during different
stages of development of atherosclerosis in humans. Key
unresolved questions include:
1. What are the key environmental cues/factors that in-
duce phenotypicmodulation/switching of VSMCs after
vessel injury or during different stages of atherogenesis?
2. What are the molecular mechanisms by which these
environmental cues/factors induce phenotypic modula-
tion of VSMCs?
3. Can the phenotypic state of VSMCs within lesions be
manipulated for therapeutic purposes?
4. What is the role of post-transcriptional regulatorymech-
anisms in control of phenotypic switching of VSMCs, an
area that is grossly understudied, particularly given the
large number of SMC-selective alternative splice prod-
ucts important for the differentiated function of the
VSMC?
5. What factors and mechanisms control VSMC pheno-
typic switching in other disease states including cancer,
pulmonary and systemic hypertension, and diabetes?
Clearly, much exciting progress has occurred in our
understanding of molecular mechanisms that regulate
VSMC differentiation in recent years, but much additional
work is needed.
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